Align Technology (ALGN)
(Delayed Data from NSDQ)
$236.97 USD
-1.09 (-0.46%)
Updated Oct 3, 2024 03:59 PM ET
After-Market: $232.00 -4.97 (-2.10%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$236.97 USD
-1.09 (-0.46%)
Updated Oct 3, 2024 03:59 PM ET
After-Market: $232.00 -4.97 (-2.10%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Zacks News
ResMed (RMD) Q4 Earnings Top, 2020 Strategic Goals on Track
by Zacks Equity Research
ResMed's Q4 results (RMD) register strong sales in sleep devices, respiratory care devices, mask systems and software solutions.
DaVita (DVA) Beats Earnings and Revenue Estimates in Q2
by Zacks Equity Research
DaVita's (DVA) stable performance across its businesses was the key highlight of the second quarter.
VWR Corp (VWR) Beats Earnings & Revenue Estimates in Q2
by Zacks Equity Research
VWR Corp (VWR) reported an impressive Q2 and is presently awaiting a merger with Avantor.
IDEXX Laboratories (IDXX) Q2 Earnings & Revenues Top, View Up
by Zacks Equity Research
IDEXX Laboratories (IDXX) rides high on strength across all segments in Q2 with significant contributions from the Companion Animal Group business. Moreover, a raised guidance buoys optimism.
Hill-Rom Holdings (HRC) Beats Q3 Earnings, Misses Revenues
by Zacks Equity Research
Hill-Rom Holdings (HRC) rides high on international growth and product innovation.
Company News For July 31, 2017
by Zacks Equity Research
Companies in the news are: EXPE,MRK,ALGN,MAT
NuVasive (NUVA) Beats on Q2 Earnings, Retains 2017 View
by Zacks Equity Research
NuVasive (NUVA) rides high on continued growth in international business in Q2. Also, the company has worked on revamping its organizational structure.
Omnicell (OMCL) Earnings Meet, Revenues Beat Estimates in Q2
by Zacks Equity Research
Omnicell (OMCL) benefited from high XT revenues and strength in IV Solutions in Q2.
AmerisourceBergen (ABC) Q3 Earnings: Will It Disappoint?
by Zacks Equity Research
AmerisourceBergen's (ABC) third-quarter performance face risks from reduced contract renewals and lower generic inflation.
Abaxis (ABAX) Misses Earnings & Revenue Estimates in Q1
by Zacks Equity Research
Despite Abaxis' lackluster performance in the fiscal first quarter, its new marketing strategies and recent launches buoy optimism.
GNC Holdings (GNC) Tops Q2 Earnings, Misses Sales Estimates
by Zacks Equity Research
Sluggish performance by the U.S. & Canada international and manufacturing/wholesale segments marred second-quarter results for GNC Holdings (GNC).
Align Technology (ALGN) Beats on Q2 Earnings and Revenues
by Zacks Equity Research
Align Technology (ALGN) rides high in Q2 banking on robust growth in the Invisalign space.
QIAGEN (QGEN) Beats on Earnings & Sales in Q2, Raises View
by Zacks Equity Research
QIAGEN (QGEN) continues to bank on the Molecular Diagnostics space for growth.
Merit Medical Systems (MMSI) Worth a Look: Stock Gains 7.7%
by Zacks Equity Research
Merit Medical Systems, Inc. (MMSI) shares rose almost 8% in the last trading session.
McKesson (MCK) Misses Earnings Estimates in Q1, Raises View
by Zacks Equity Research
McKesson's (MCK) performance was muted in the first quarter owing to branded to generic conversions and competition in its pharmacy business.
Integra LifeSciences (IART) Q2 Earnings Meet, Revenues Miss
by Zacks Equity Research
Integra LifeSciences' (IART) solid performance in the Orthopedics and Tissue Technologies was the key highlight of the second quarter.
CONMED (CNMD) Earnings Meet, Revenues Beat Estimates in Q2
by Zacks Equity Research
CONMED's (CNMD) strong global performance was a key highlight in the second quarter of 2017.
LabCorp (LH) Beats on Q2 Earnings and Sales, Guidance Up
by Zacks Equity Research
LabCorp's (LH) dull Covance Drug Development performance is offset by solid growth in Diagnostics. Increased guidance raises hope.
Med-Products' Q2 Earnings Roster for Jul 27: ALGN, BSX & More
by Zacks Equity Research
The ongoing conflict related to healthcare policy implementation in the U.S. might get reflected in the Q2 results of these companies.
Chemed (CHE) Q2 Earnings & Revenues Rise Y/Y, View Revised
by Zacks Equity Research
Chemed (CHE) rides high on Roto-Rooter in second-quarter 2017. An encouraging bottom-line projection raises hopes.
Should You Buy Align Technology (ALGN) Ahead of Earnings?
by Zacks Equity Research
Align Technology (ALGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.
Express Scripts (ESRX) Earnings Top in Q2, FY17 View Up
by Zacks Equity Research
Express Scripts (ESRX) perform well in the second quarter on the back of operational cost improvement backed by focus on home delivery and specialty services.
What to Expect from International Paper (IP) in Q2 Earnings?
by Zacks Equity Research
Fluctuations in actual equity market returns, changes in general interest rates are likely to hurt International Paper (IP) in Q2 earnings.
VASCO (VDSI) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Vasco's (VDSI) focus on generating high operating margins, backed by continuous investments and a shift in the product mix with higher gross-margin products, is likely to boost its Q2 earnings.
PetMed Express (PETS) Tops Earnings, Revenue Estimates in Q1
by Zacks Equity Research
PetMed (PETS) initiated fiscal 2018 with better-than-expected results in the first quarter, beating both earnings and revenues.